Clareo Health | Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
King's College London
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-65 years.
Clinical diagnosis of schizophrenia (i.e. documented as such in the patient's clinical records and satisfying ICD-10 criteria for F20)
Clinically stable for at least three months (since discharge from hospital, home treatment team, or prior clinical deterioration, and with agreement from the patient's responsible clinician)
Regular (at least weekly) cannabis use for the past 3 months or more
Evidence from either clinicians or from the patient that cannabis use exacerbates their symptoms or increases their risk of relapse
Treatment with regular doses of antipsychotic medication for at least 1 month, confirmed by a blood test at the baseline visit, and with the participant agreeing to be maintained at a stable dose over the course of the experiment
The participant agrees to abstain from cannabis use for at least 24hours prior to study visits
The participant is willing to have an intravenous cannula inserted to collect blood samples on experimental visits
Sufficiently fluent English
Providing written informed consent
You may not be if
Extreme cannabis use: participant is estimate to be using over 1gram of cannabis/day
Dependence on alcohol or illicit substances other than cannabis as defined by ICD-10
Pregnancy (current or planned) or breastfeeding
Physical health disorder or another mental health disorder that the study psychiatrist judges may influence the patient's ability to tolerate the procedure, or that may alter the results of the study.
Taken part in any drug study within the last 3 months or taking part in another study over the course of the trial
Drug sensitivity/allergy to cannabis or Lorazepam
Unlikely to be able to complete the study sessions for any reason, as judged by the study psychiatrist
Additional criteria which must be met on experimental visits:
Negative alcohol breath test
Negative urine drug screen (apart from cannabis and prescribed medication)
Negative urine pregnancy test
Stable mental state as judged by the study psychiatrist
